The pipeline of Zealand Pharma AS of Denmark is advancing strongly towards a catalyst-filled 2020 that the biotech hopes bring it four US drug approvals and lead to subsequent commercial launches starting from 2021, its CEO told Scrip in an interview.
Zealand Pharma Preps Pipeline For Catalyst-Filled 2020
Biotech’s CEO Hopes For Four US approvals In 2020
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.
More from Business
More from Scrip
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.